New data recently presented at the 2015 American College of Rheumatology Annual Meeting in San Francisco showed that mycophenolate mofitil is as efficient as cyclophosphamide for the treatment of interstitial lung disease in individuals with scleroderma. Scleroderma, or systemic sclerosis, is a chronic systemic autoimmune disease characterized by a…
News
Researchers at St. Elizabeth’s Medical Center in Stow, Massachusetts, recently reported a clinical case of pulmonary lymphoma in a patient diagnosed with scleroderma. The data was presented at the American College of Chest Physicians Annual Meeting (CHEST 2015), held Oct. 24–28 in Montreal, Canada, under the title “…
What is it like living with scleroderma? This video takes a look at some of the struggles that patients face when dealing with this life altering autoimmune disease. The video features actor, Jason Alexander; Football Hall of Famer, Barry Sanders; Actor and Comedian, Mark Teich; Author and Personality,…
In a new research paper, scientists at the Faculty of Dentistry, Aristotle University of Thessaloniki, Greece, presented a clinical report of a systemic sclerosis case where the jaw was affected. The research paper, whose goal is to raise awareness among oral radiologists and other health professionals, is entitled “…
In a new study entitled “Systemic Sclerosis Patients Present Alterations in the Expression of Molecules Involved in B-Cell Regulation,” a team of researchers investigated whether patients with systemic sclerosis present changes in their immune B cells profile (including frequency and activation phenotypes), focusing particularly on the B…
iBio, Inc., a plant-based biotechnology company focused on developing biological therapies for several fibrotic diseases including idiopathic pulmonary fibrosis and systemic sclerosis, recently announced it has received a notification from the European Patent Office stating that the opposition period for the iBio patent 2192172, entitled “System for Expression of…
Reata Pharmaceuticals, Inc., a biopharmaceutical company based in Irving, Texas, recently announced positive data from the Phase 2 clinical trial LARIAT assessing the company’s candidate product bardoxolone methyl for pulmonary arterial hypertension (PAH). The results were recently presented by Dr. Ronald Oudiz, Director of the Pulmonary Hypertension Center and…
Cytori Therapeutics, Inc., a company focused on therapeutics and devices in the field of regenerative medicine, recently reported it has enrolled and administered treatment to the first patient in its ongoing SCLERADEC-II trial, a late phase, follow-on European study that aims to evaluate the efficacy and safety profile of Cytori…
A recent study identified a novel molecule implicated in the development of skin fibrosis, a serious disease characterized by the inflammation and hardening of skin tissue. The study entitled “The matrix protein Fibulin-5 lies at the interface of tissue stiffness and inflammation in fibrosis” was recently published…
Researchers Identify Potential Genetic Pathways of Systemic Sclerosis-Associated Pulmonary Fibrosis
In a recent study entitled “Molecular network of important genes for systemic sclerosis-related progressive lung fibrosis”, published in the BMC Research Notes journal, a team of researchers from the US and China established the expression levels of crucial genes for Systemic Sclerosis-related progressive pulmonary…
Recent Posts
- More SSc-ILD patients receive early treatment, new study finds
- CD13 levels elevated in scleroderma, but biomarker value unclear
- New lab findings support development of stem cell treatments for SSc-ILD
- Type of immune cell may be key driver of scleroderma scarring: Study
- Abnormal fatty acid metabolism may play role in scleroderma: Analysis
- Cosmetic laser therapy could be repurposed for localized scleroderma
- Antibody levels may help reflect quality of life in people with scleroderma
- Certain antibodies tied to poorer outcomes in systemic sclerosis
- Dexamethasone reduces inflammation, scarring in SSc mouse model: Study
- Survival improves for SSc-PAH patients on combination therapy